Leischik R, Beller K D, Erbel R
University Essen, FRG.
Basic Res Cardiol. 1996 Jan-Feb;91(1):101-9. doi: 10.1007/BF00788871.
Transpulmonary echo contrast agents improve the evaluation of left ventricular function by two-dimensional echocardiography due to a better endocardial border delineation. To compare the contrast effect in the right and left ventricular cavities, a new transpulmonary echocontrast agent, BY 963 and Albunex were intravenously administered to five non-anaesthetized dogs. The right and left ventricular echocardiographic image intensities were quantitatively measured at 60 cardiac cycles using a commercially available ultrasound system. BY 963 and Albunex were intravenously administered at three doses: 0.01 ml/Kg, 0.05 ml/Kg and 0.1 ml/Kg. The area under the curve (AUC, intensity units x heart cycles) and peak intensity (Peak I, intensity units) were estimated for the right (RV) and left ventricular (LV) cavities at the mid ventricular level using acoustic intensitometry. BY 963 injection produced the following values: At the dose of 0.01, 0.05 and 0.1 ml/Kg the AUC amounted to 702 +/- 449, 877 +/- 470 and 890 +/- 320 intensity units x heart cycles in RV and to 542 +/- 406, 806 +/- 557 and 721 +/- 392 in LV (LV/RV ratios: 77%, 92% and 81%). Peak I was at the doses 0.01, 0.05 and 0.1 ml/Kg 29 +/- 4.7, 33 +/- 5.2 and 35 +/- 3.2 intensity units in RV and 18 +/- 5.9, 21 +/- 6.2 and 20 +/- 3.3 in LV (LV/RV ratios: 62%, 64% and 57%). Albunex also produced right and left heart opacification values: at the doses 0.01, 0.05 and 0.1 ml/Kg the AUC amounted to 416 +/- 231, 493 +/- 231 and 674 +/- 390 in RV and to 71 +/- 71, 158 +/- 102 and 277 +/- 120 in LV (LV/RV ratios: 17%, 34% and 41%). Peak I was at the doses of 0.01, 0.05 and 0.1 ml/Kg 19 +/- 5.2, 23 +/- 5.4 and 29 +/- 4.1 in RV and 8 +/- 4.8, 13 +/- 4.7 and 17 +/- 3.2 in LV (LV/RV ratios: 42%, 57% and 59%). Intravenous injection of BY 963 leads to complete opacification of the left ventricular cavity and to high AUC values and peak intensity values at all three dosages. The loss of contrast effect from the right to the left ventricular cavity was very low: the LV/RV ratio of BY 963 was higher than that of Albunex. The new transpulmonary echo contrast agent BY 963 promises to be an excellent echo contrast agent for the noninvasive assessment of left ventricular function.
经肺超声造影剂可通过更好地勾勒心内膜边界，改善二维超声心动图对左心室功能的评估。为比较右心室和左心室腔的造影效果，将一种新型经肺超声造影剂BY 963和Albunex静脉注射给5只未麻醉的犬。使用市售超声系统在60个心动周期定量测量右心室和左心室的超声心动图图像强度。BY 963和Albunex以三种剂量静脉注射：0.01 ml/Kg、0.05 ml/Kg和0.1 ml/Kg。使用声学强度测定法在心室中部水平估计右心室（RV）和左心室（LV）腔的曲线下面积（AUC，强度单位×心动周期）和峰值强度（Peak I，强度单位）。注射BY 963产生以下值：在0.01、0.05和0.1 ml/Kg剂量下，RV的AUC分别为702±449、877±470和890±320强度单位×心动周期，LV的AUC分别为542±406、806±557和721±392（LV/RV比值：77%、92%和81%）。Peak I在0.01、0.05和0.1 ml/Kg剂量下，RV分别为29±4.7、33±5.2和35±3.2强度单位，LV分别为18±5.9、21±6.2和20±3.3（LV/RV比值：62%、64%和57%）。Albunex也产生了右心和左心显影值：在0.01、0.05和0.1 ml/Kg剂量下，RV的AUC分别为416±231、493±231和674±390，LV的AUC分别为71±71、158±102和277±120（LV/RV比值：17%、34%和41%）。Peak I在0.01、0.05和0.1 ml/Kg剂量下，RV分别为19±5.2、23±5.4和29±4.1强度单位，LV分别为8±4.8、13±4.7和17±3.2（LV/RV比值：42%、57%和59%）。静脉注射BY 963可使左心室腔完全显影，且在所有三种剂量下均具有高AUC值和峰值强度值。从右心室腔到左心室腔的造影效果损失非常低：BY 963的LV/RV比值高于Albunex。新型经肺超声造影剂BY 963有望成为用于无创评估左心室功能的优秀超声造影剂。
